Copper-Bearing Metal-Organic Framework with Mucus-Penetrating Function for the Multi-Effective Clearance of Mucosal
Chunxi Shu1, Wei Zhang1,2, Yiwei Zhang3
1Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College Nanchang University, Nanchang 330006, China.
Abstract:
Helicobacter pylori colonizes over 50% of people worldwide. Biofilm formation through penetrating gastric mucus and resistance acquired by H. pylori markedly reduces the efficacy of traditional antibiotics. The present triple therapy and bismuth-based quadruple therapy inevitably causes intestinal flora disturbance and fails to address the excessive H. pylori-triggered inflammatory response. Herein, a mucus-permeable therapeutic platform (Cu-MOF@NF) that consists of copper-bearing metal-organic framework (Cu-MOF) loaded with nitrogen-doped carbon dots and naturally active polysaccharide fucoidan is developed. The experimental results demonstrate that Cu-MOF@NF can penetrate the mucus layer and hinder H. pylori from adhering on gastric epithelial cells of the stomach. Notably, released Cu2+ can degrade the polysaccharides in the biofilm and interfere with the cyclic growing mode of "bacterioplankton ↔ biofilm", thereby preventing recurrent and persistent infection. Compared with traditional triple therapy, the Cu-MOF@NF not only possesses impressive antibacterial effect (even include multidrug-resistant strains), but also improves the inflammatory microenvironment without disrupting the balance of intestinal flora, providing a more efficient, safe, and antibiotic-free new approach to eradicating H. pylori.
Insights
A novel mucus-permeable platform, Cu-MOF@NF, effectively eradicates Helicobacter pylori by disrupting biofilms and improving the inflammatory environment. This antibiotic-free approach offers a safer alternative to traditional therapies for persistent H. pylori infections.
Area of Science:
- Biomedical Engineering
- Materials Science
- Microbiology
Background:
- Helicobacter pylori infection affects over 50% of the global population.
- Antibiotic resistance and biofilm formation in H. pylori reduce treatment efficacy.
- Current therapies cause gut flora imbalance and fail to manage inflammation.
Purpose of the Study:
- To develop a mucus-permeable therapeutic platform for H. pylori eradication.
- To overcome challenges posed by H. pylori biofilms and antibiotic resistance.
- To provide a safe, antibiotic-free alternative for H. pylori treatment.
Main Methods:
- Development of a copper-bearing metal-organic framework (Cu-MOF) loaded with nitrogen-doped carbon dots and fucoidan (Cu-MOF@NF).
- Evaluation of Cu-MOF@NF's ability to penetrate gastric mucus and inhibit H. pylori adhesion.
- Assessment of Cu2+ release for biofilm degradation and interference with bacterial growth modes.
- Comparison of Cu-MOF@NF efficacy against traditional triple therapy.
Main Results:
- Cu-MOF@NF successfully penetrated the mucus layer and prevented H. pylori adhesion.
- Released Cu2+ degraded biofilm polysaccharides and disrupted bacterial growth cycles.
- Cu-MOF@NF demonstrated potent antibacterial effects, including against multidrug-resistant strains.
- The platform improved the inflammatory microenvironment without disrupting intestinal flora.
Conclusions:
- Cu-MOF@NF is an effective, antibiotic-free therapeutic platform for H. pylori eradication.
- The platform prevents recurrent infections by targeting biofilms and inflammation.
- Cu-MOF@NF offers a safer and more efficient alternative to conventional H. pylori treatments.
More Related Videos
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:25Mucosal Barrier of the Stomach
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.